Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Hisse Senetlerindeki Sıralama #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Hisse Fiyatı
$62.49
Son senkronizasyon: 2024-03-06
Piyasa Değeri
$2.52B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret RayzeBio, Inc. Common Stock (RYZB)

Kategori

RayzeBio, Inc. Common Stock (RYZB) için EPS
2026 itibariyle EPS TTM: 0
RayzeBio, Inc. Common Stock şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
RayzeBio, Inc. Common Stock için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS
Şirket EPS EPS Farkı Ülke
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH